Highly Reproducible Detection and Semi-Quantification of Telomerase Activity by S. Verstovsek, T. Manshouri, H. Kantarjian, F.J. Giles, M. Keating, E. Estey, M. Albitar

Get full text

P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML by A. Bidikian, H. Kantarjian, E. Jabbour, N. Short, F. Ravandi, G. Issa, K. Sasaki

Get full text

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER by L. Masarova, P. Bose, N. Pemmaraju, H. Chifotides, L. Zhou, Z. Estrov, H. Kantarjian, S. Verstovsek

Get full text

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS by S. P. Desikan, G. Montalban-Bravo, M. Ohanian, N. Daver, T. Kadia, S. Venugopal, K. Chien, H. Kantarjian, G. Garcia-Manero

Get full text

P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGI... by T. Abuasab, J. Senapati, T. Kadia, F. Ravandi, C. DiNardo, N. Pemmaraju, M. Ohanion, Y. Alvarado, H. Kantarjian, G. Borthakur

Get full text

P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS by J. Senapati, S. Verstovsek, L. Masarova, N. Pemmaraju, G. Montalban Bravo, S. Pierce, L. Zhou, G. Garcia-Manero, H. Kantarjian, P. Bose

Get full text

P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML by J. Senapati, F. Haddad, F. Ravandi, T. Kadia, C. DiNardo, N. Daver, N. Pemmaraju, Y. Alvarado, M. A. Brandt, H. Kantarjian, G. Borthakur

Get full text

P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS by F. Haddad, H. Kantarjian, E. Jabbour, N. Short, A. Bidikian, J. Ning, L. Xiao, N. Pemmaraju, K. Marx, F. Ravandi, K. Sasaki, G. Issa

Get full text

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PH... by E. Jabbour, G. Martinelli, M. Vignetti, H. Kantarjian, D. Gomez-Almaguer, Y. Minami, H. Dombret, M. Hennessy, A. Vorog, B. Wang, J.-M. Ribera

Get full text

P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES by S. Venugopal, H. Song, C. Young, M. A. Cutherell, J. A. Baganz, S. Zatorsky, S. E. Woodman, N. Pemmaraju, P. Bose, L. Masarova, L. Zhou, S. Pierce, H. Kantarjian, S. Verstovsek

Get full text

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34) by F. Ong, T. M. Kadia, N. J. Short, M. Yilmaz, Y. Alvarado, S. Pierce, G. Garcia-Manero, C. DiNardo, G. Borthakur, M. Konopleva, N. Daver, H. Kantarjian, F. Ravandi

Get full text

S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL by G. Montalban-Bravo, F. Ma, I. Ganan-Gomez, R. Kanagal-Shamana, V. Adema, N. Thongon, H. Yang, K. A. Soltysiak, C. Bueso-Ramos, H. Kantarjian, G. Garcia-Manero, S. Colla

Get full text

P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) by T. Kadia, F. Ravandi, G. Borthakur, E. Jabbour, G. Montalban-Bravo, L. Adewale, S. Pierce, C. Lacke, M. Brandt, N. Short, N. Jain, J. Burger, A. Ferrajoli, W. Wierda, H. Kantarjian

Get full text

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC L... by S. Venugopal, H. kantarjian, A. Maiti, N. Short, G. Montalban-Bravo, Y. Alvarado, K. S. Chien, R. Kanagal-Shamanna, N. Pemmaraju, N. Daver, T. Kadia, G. Borthakur, E. Jabbour, G. Garcia-Manero

Get full text

P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME by K. Kim, K. Chien, O. Faustine, G. Montalban-Bravo, R. Kanagal-Shamanna, T. Kadia, E. Jabbour, Y. Alvarado, K. Sasaki, X. Q. Dong, S. Pierce, C. Bueso-Ramos, H. Kantarjian, G. Garcia-Manero

Get full text

P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEM... by A. Bazinet, T. Kadia, N. Short, G. Borthakur, S. Wang, S. Loghavi, J. Jorgensen, K. Patel, C. DiNardo, N. Daver, Y. Alvarado, F. Haddad, S. Pierce, M. Andreeff, E. Jabbour, M. Konopleva, H. Kantarjian, F. Ravandi

Get full text

P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB by W. Macaron, E. Jabbour, M. Konopleva, F. Ravandi, N. Jain, G. Issa, T. Kadia, K. Sasaki, P. Kebriaei, M. Yilmaz, P. Thompson, K. Takahashi, H. Abbas, W. Wierda, R. Garris, H. Kantarjian, N. Short

Get full text

P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES by K. Chien, K. Kim, Z. Li, R. Kanagal Shamanna, F. Ong, G. Montalban Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero

Get full text

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS by S. Venugopal, E. Jabbour, N. Pemmaraju, G. Montalban-Bravo, K. S. Chien, N. Daver, N. Jain, J. Burger, Y. Alvarado, A. Maiti, C. D. DiNardo, G. Borthakur, R. Malla, G. Garcia-Manero, F. Ravandi, H. Kantarjian, T. Kadia

Get full text

P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE by K. Kim, F. Ong, Z. Li, R. Kanagal-Shamanna, G. Montalban-Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero, K. Chien

Get full text